

of RNA that binds to both the enzyme and the target DNA⁹. This approach is also known as CRISPR–Cas gene editing. The guide RNA matches the mutant but not the wild-type gene, enabling Gao and colleagues to solve the problem of ensuring that the mutant form of the gene is cut whereas the wild-type version is left untouched.

Another challenge was to get Cas9 into the inner ear. *In vivo* gene-editing approaches often rely on viruses to introduce nuclease-encoding sequences into the organism being edited^{10,11}. However, Gao and colleagues reasoned that, when the nuclease has done its job in the cell, it will no longer be required, so introducing the protein itself should suffice. They turned to a technique they had used previously¹², in which they packaged Cas9 protein bound to its guide RNA in a type of lipid droplet that can fuse with cells, enabling the editing machinery to enter. The authors injected these droplets into the inner ear of newborn Beethoven mice.

The inner ears of unedited adult Beethoven mice were barren of hair cells; however, their gene-edited adult siblings had inner-ear hair cells that were almost indistinguishable in shape and number from those in wild-type mice. The edited animals could be startled by a sudden loud noise, whereas their unedited siblings could not. More-sophisticated measurements also confirmed that hearing improved as a result of gene editing. Encouragingly, the engineered nuclease seems to have stayed true to its design and did not create undesired genetic changes of concern in the DNA of the hair cells.

A modest fraction of cells were edited. The authors propose that this low proportion of edited cells resulted in a beneficial ‘halo’-like effect on neighbouring unedited cells that still contained the mutant form of the gene, preventing the death and degeneration of these neighbouring cells. Although the mechanism underlying this proposed halo effect is unclear, the finding offers encouragement for the clinical adoption of this approach, because it suggests that the genetic repair of all hair cells is perhaps not needed to achieve a beneficial effect on hearing.

Gao and colleagues’ work provides an essential first step towards moving this type of approach nearer to the clinic by providing evidence that it is safe and effective in an animal that has a similar genetic mutation and comparable hearing loss to those in humans. How long could it be before individuals with this *TMC1* mutation might be treated using gene editing? One reason for optimism comes from the pace at which other gene-editing approaches have reached the clinic.

To give just a few examples from clinical trials, the gene *CCR5* has been inactivated in immune-system cells using a type of enzyme called a zinc-finger nuclease to try to reduce the viral load in people infected with

HIV¹³. Immune cells have also been edited to generate cancer-targeting cells¹⁴. However, these techniques required cells to be removed from the patient’s body for gene editing and then replaced. Ear cells cannot be removed, so a direct *in vivo* approach is needed, which is even more challenging to achieve than *ex vivo* gene editing.

Encouragingly, such *in vivo* gene editing (for a different condition) has been performed in a clinical trial using zinc-finger nucleases¹⁵, and the work leading up to that¹⁶ makes clear the next steps for Gao and colleagues’ approach. A nuclease must be found that has clinical-grade potency and specificity in human cells. Lipids must be identified that can be safely injected along with the nuclease into the human inner ear. Next, this nuclease must be tested for safety in larger animals, such as primates. An *in vivo* virus-based gene therapy for direct injection into the eye¹⁷ has been recommended for approval in the United States, and that work provides a road map for the scientific, medical and commercial considerations that need to be taken into account when moving to the clinic.

In 1902, the physician Archibald Garrod initiated the first study that demonstrated a link between a gene and a disease. Since then, more than 5,000 diseases have been linked to single-gene changes. However, without the tools to modify disease-causing forms of genes, geneticists have often been unable to see their knowledge put to use for clinical benefit. The

progress being made with genome editing is changing this. Although Beethoven never heard his famous *Ode to Joy*, it could be that — thanks in no small part to his murine namesake’s fateful encounter with Cas9 — we are getting closer to the day when individuals with deafness-causing mutations can be treated by gene editing to prevent hearing loss. ■

Fyodor Urnov is at the *Altius Institute for Biomedical Sciences, Seattle, Washington 98121, USA.*

e-mail: urnov@altius.org

1. Gao, X. *et al. Nature* **553**, 217–221 (2018).
2. Fettiplace, R. & Kim, K. X. *Physiol. Rev.* **94**, 951–986 (2014).
3. Kawashima, Y. *et al. J. Clin. Invest.* **121**, 4796–4809 (2011).
4. Kurima, K. *et al. Nature Genet.* **30**, 277–284 (2002).
5. Zhao, Y. *et al. PLoS ONE* **9**, e97064 (2014).
6. Vreugde, S. *et al. Nature Genet.* **30**, 257–258 (2002).
7. Pan, B. *et al. Neuron* **79**, 504–515 (2013).
8. Carroll, D. *Ann. Rev. Biochem.* **83**, 409–439 (2014).
9. Jiang, F. & Doudna, J. A. *Annu. Rev. Biophys.* **46**, 505–529 (2017).
10. Li, H. *et al. Nature* **475**, 217–221 (2011).
11. Ran, F. A. *et al. Nature* **520**, 186–191 (2015).
12. Zuris, J. A. *et al. Nature Biotechnol.* **33**, 73–80 (2014).
13. Tebas, P. *et al. N. Engl. J. Med.* **370**, 901–910 (2014).
14. Qasim, W. *et al. Sci. Transl. Med.* **9**, eaaj2013 (2017).
15. <https://clinicaltrials.gov/ct2/show/NCT03041324>
16. Sharma, R. *et al. Blood* **126**, 1777–1784 (2015).
17. Russell, S. *et al. Lancet* **390**, 849–860 (2017).

This article was published online on 20 December 2017.

MATERIALS SCIENCE

Rule-breaking perovskites

A material from the perovskite family of semiconductors emits light much more efficiently than expected. The explanation for this anomalous behaviour could lead to improvements in light-emitting technology. SEE LETTER P.189

MICHELE SABA

When a semiconductor absorbs light, a particle-like entity called an exciton can be produced. Excitons comprise an electron and a hole (the absence of an electron), and have two possible states: singlet and triplet. Triplet states were thought to be poor emitters of light, but, on page 189, Becker *et al.*¹ report that semiconductors known as lead halide perovskites have bright triplet excitons. The results could signify a breakthrough in optoelectronics because triplet states are three times more abundant than singlet states² and currently limit the efficiency of organic light-emitting diodes³.

Conventional wisdom holds that triplet states are dark because of the spin selection rule⁴, which forbids electrons from changing their intrinsic angular momentum (spin) during an optical transition — the process in which an atom or molecule switches from one energy state to another by emitting or absorbing light. The rule is taught in quantum-mechanics classes when atomic transitions are first introduced, and is so general that one might think that it is written in stone. Fortunately, there are loopholes that can be exploited.

The search for emissive triplet states has focused on a certain principle of quantum mechanics: if an electron’s spin is coupled




Figure 1 | Exciton emission. Semiconductors contain electrons and holes (absences of electrons) that can combine to form bound states called excitons. **a**, In singlet excitons, the intrinsic angular momenta (spins) of the electron and the hole point in opposite directions, which facilitates the emission of light. **b**, Conversely, in triplet excitons, the spins point in the same direction. Conventional wisdom holds that such states are dark, but Becker *et al.*¹ report that semiconductors known as lead halide perovskites emit light through bright triplet excitons.

to another form of angular momentum (namely, orbital momentum), the sum of the two momenta needs to be conserved, rather than the spin alone. The effect is known as spin–orbit coupling in atomic physics and as intersystem crossing in the study of organic semiconductors. It is responsible for weak emission from triplet states in atoms and organic molecules, especially when heavy elements are involved. However, until now, the strength of triplet emission was thought always to be inferior to that of singlet emission.

Lead halide perovskites seem to dispose of all conventional wisdom in materials science. Like organic semiconductors, they are relatively easy to fabricate, and their bandgap (a property that determines their conductivity and optical properties) can be tuned by varying their composition. Yet, like thin-layer (epitaxial) inorganic semiconductors, they are highly crystalline and exhibit efficient charge transport. It is as if their properties were selected from a materials scientist's wish list, combining the best aspects of organic molecules, nanocrystals and epitaxial inorganic semiconductors.

Becker and colleagues' study suggests that there is another feature of lead halide perovskites to be added to this list. The authors used a combination of theoretical and experimental work to show that nanocrystals of caesium lead halide perovskites (CsPbX_3 , where X is chlorine, bromine or iodine) have bright triplet excitons (Fig. 1). This property results in an emission rate surpassing that of other known nanocrystals⁵.

The energy difference between the triplet and singlet states in CsPbX_3 nanocrystals is relatively small (of the order of 1 millielectronvolt). Becker *et al.* therefore explored the material's emission at cryogenic temperatures (a few kelvin), to prevent

transitions between triplet and singlet states. It is unclear to what extent bright triplet states affect the material's emission efficiency at room temperature — when thermal energy greatly exceeds the singlet–triplet splitting energy and all states are equally populated. Nevertheless, the authors' findings are of fundamental relevance.

Future work will certainly investigate whether bright triplet states exist in other types of perovskite, such as hybrid perovskites that have organic, positively charged ions (cations). Such materials include the archetypal methylammonium lead iodide ($\text{CH}_3\text{NH}_3\text{PbI}_3$), and are typically prepared not as nanocrystals,

“The authors' study highlights the potential of perovskite materials as efficient light emitters.”

but as solid-state films⁶. Unlike CsPbX_3 nanocrystals, these films comprise micrometre- or millimetre-sized crystalline domains, in which excitons dissociate into pairs of free electrons and holes at room temperature. More generally, Becker and colleagues' theoretical analysis might help scientists to identify other semiconducting materials (either organic or inorganic) that have bright triplet excitons.

Research into hybrid perovskites has been fuelled in the past few years by the successful incorporation of these materials into solar cells. Such devices can now convert more than 22% of the energy received from sunlight into electricity⁷, which is a record for perovskite solar cells. However, because of a concept known as quantum-mechanical reciprocity, there is an unavoidable energy loss in solar cells: that due to photoluminescence, which is the reverse of the absorption process⁸. As a consequence, the best solar cells are also the

best light emitters — an idea reinforced by Becker and colleagues' work.

Perovskite solar cells are now leaving academic labs and entering the market, thanks to substantial industrial efforts. The competition is mainly silicon solar cells, which have become so cheap that they negate some of the advantages of perovskite fabrication. For this reason, tandem solar cells (consisting of two sub-cells) and innovative architectures involving perovskites are being developed that can outperform commercial silicon devices in terms of efficiency, if not cost⁹.

Light emission is an application in which organic semiconductors and nanocrystals have already found commercial success, because of their ability to produce vivid colours and to be incorporated into thin panels. And yet the electric-current densities in organic light-emitting diodes are much lower than in their inorganic counterparts as a result of poor electrical conductivity. Perovskites could allow high current densities and efficiencies to be realized on large-area, thin panels¹⁰.

Becker and colleagues' study highlights the potential of perovskite materials as efficient light emitters. Although the findings might seem surprising at first sight, they should be seen as a natural consequence of quantum-mechanical reciprocity — that the class of material brought to the forefront by solar-cell technology could find applications in light emission. ■

Michele Saba is in the Department of Physics, University of Cagliari, I-09042 Monserrato, Italy.

e-mail: saba@unica.it

1. Becker, M. A. *et al.* *Nature* **553**, 189–193 (2018).
2. Pope, M. & Swenberg, C. E. *Electronic Processes in Organic Crystals* (Oxford Univ. Press, 1999).
3. Reineke, S., Thomschke, M., Lüssem, B. & Leo, K. *Rev. Mod. Phys.* **85**, 1245–1293 (2013).
4. Demtröder, W. *Atoms, Molecules and Photons* (Springer, 2010).
5. Rainò, G. *et al.* *ACS Nano* **10**, 2485–2490 (2016).
6. Stoumpos, C. C. & Kanatzidis, M. G. *Acc. Chem. Res.* **48**, 2791–2802 (2015).
7. Correa-Baena, J.-P. *et al.* *Science* **358**, 739–744 (2017).
8. Rau, U. *Phys. Rev. B* **76**, 085303 (2007).
9. Eperon, G. E., Hörantner, M. T. & Snaith, H. J. *Nature Rev. Chem.* **1**, 0095 (2017).
10. Colella, S., Mazzeo, M., Rizzo, A., Gigli, G. & Listorti, A. *J. Phys. Chem. Lett.* **7**, 4322–4334 (2016).

CORRECTION

The News & Views article ‘Cancer: Tumour lymph vessels boost immunotherapy’ by Christine Moussion and Shannon J. Turley (*Nature* **552**, 340–342; 2017) cited reference 2 incorrectly. The correct reference is: S. L. Topalian, C. G. Drake & D. M. Pardoll *Cancer Cell* **27**, 450–461 (2015).